TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39262426

Group type: EXPERIMENTAL
Intervention: Larger maximal lifetime brain growth (MLBG)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 383
Study: 39262580

Group type: EXPERIMENTAL
Intervention: Global Postural Re-education (GPR) self-management program
Number of subjects: 41
Study: 39262902

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 0
Study: 39262903

Group type: EXPERIMENTAL
Intervention: Shi's manual therapy (SMT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Merislon (Betahistine Mesilate Tablets)
Number of subjects: 106
Study: 39263280

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine 2 mg/kg (Group K)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Esketamine 1 mg/kg and dexmedetomidine 1 µg/kg (Group KD1)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Esketamine 0.5 mg/kg and dexmedetomidine 2 µg/kg (Group KD2)
Number of subjects: 180
Study: 39263388

Group type: EXPERIMENTAL
Intervention: Community-Based Training for Musculoskeletal Health Promotion
Number of subjects: 0
Study: 39263597

Group type: EXPERIMENTAL
Intervention: Once-nightly sodium oxybate (ON-SXB, FT218)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Twice-nightly immediate-release (IR) oxybate
Number of subjects: 130
Study: 39263755

Group type: EXPERIMENTAL
Intervention: Laparoscopy (LTME)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Laparotomy (OTME)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery (RTME)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Transanal surgery (TaTME)
Number of subjects: 1078
Study: 39263892

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with nab-paclitaxel plus systemic gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic treatment comprising gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Number of subjects: 0
Study: 39264028

Group type: EXPERIMENTAL
Intervention: Uroflowmetry curve interpretation by four investigators
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Uroflowmetry curve interpretation by each investigator (intraterater reliability)
Number of subjects: 296
Study: 39264062

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultralow anterior resection using a new articulating device
Number of subjects: 0
Study: 39264108

Group type: EXPERIMENTAL
Intervention: eHealth intervention group (12 interactive modules on PA, DB, and sleep delivered weekly)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (weekly brochures on PA, DB, and sleep recommendations)
Number of subjects: 206
Study: 39264399

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 0
Study: 39264438

Group type: EXPERIMENTAL
Intervention: Vitamin D3 70 µg/day (2800 IU)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (ATD)
Number of subjects: 86
Study: 39264499

Group type: EXPERIMENTAL
Intervention: CINDERELLA APProach (AI cloud-based platform)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CINDERELLA APProach
Number of subjects: 0
Study: 39264503

Group type: EXPERIMENTAL
Intervention: 20 mg of rosuvastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: 40 mg of atorvastatin
Number of subjects: 80
Study: 39264535

Group type: EXPERIMENTAL
Intervention: Glenohumeral hydrodistension combined with bursal injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Glenohumeral hydrodistension alone
Number of subjects: 36
Study: 39264599

Group type: EXPERIMENTAL
Intervention: MYL-1701P (0.5-mg vial) every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Number of subjects: 355

Group type: COMPARATOR
Intervention: Reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: MYL-1701P
Number of subjects: 355

Group type: COMPARATOR
Intervention: Reference aflibercept
Number of subjects: 355
Study: 39264623

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 1465
Study: 39264640

Group type: EXPERIMENTAL
Intervention: Tonotopic map
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional map
Number of subjects: 26
Study: 39264682

Group type: EXPERIMENTAL
Intervention: Affect labeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 39264960

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) / Chloroquine (CQ)
Number of subjects: 4652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4652
Study: 39265124

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg once every 3 weeks
Number of subjects: 732

Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (ICC)
Number of subjects: 732
Study: 39265161

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine diagnostic tools
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Contemporary diagnostic devices
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Health Evaluation Questionnaire, Physical Activity Questionnaire, sugar intake assessment, Constitution in Chinese Medicine Questionnaire, radial pulse diagnosis, and tongue diagnosis
Number of subjects: 250
Study: 39265169

Group type: EXPERIMENTAL
Intervention: AG-348 (mitapivat), a pyruvate kinase activator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AG-348 (mitapivat)
Number of subjects: 0
Study: 39265173

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 39265255

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 10

Group type: COMPARATOR
Intervention: Overground walking
Number of subjects: 10
Study: 39265466

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin (PC) - 6 cycles of P 175 mg/m2 and C AUC=6 IV every 3 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bleomycin, Etoposide, and Cisplatin (BEP) - 4 cycles of B 20 units/m2 IV push day 1, E 75 mg/m2 IV days 1-5, and Cisplatin 20 mg/m2 IV days 1-5 every 3 weeks
Number of subjects: 63
Study: 39265579

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 21 days until disease progression or unacceptable toxicity.
Number of subjects: 7
Study: 39265599

Group type: EXPERIMENTAL
Intervention: Plinabulin plus docetaxel (n=278)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Docetaxel plus placebo (n=281)
Number of subjects: 559
Study: 39265613

Group type: EXPERIMENTAL
Intervention: fedratinib 400 mg per day
Number of subjects: 201

Group type: COMPARATOR
Intervention: best available therapy (BAT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: fedratinib
Number of subjects: 201

Group type: COMPARATOR
Intervention: BAT
Number of subjects: 201
Study: 39265782

Group type: EXPERIMENTAL
Intervention: ACT1VATE (five-week ACT group telehealth intervention)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (diabetes self-management education and support)
Number of subjects: 250
Study: 39265784

Group type: EXPERIMENTAL
Intervention: Motor-cognitive training (dual-tasks) for 20 weeks
Number of subjects: 0
Study: 39265915

Group type: EXPERIMENTAL
Intervention: Implementation strategies addressing barriers such as staff availability, knowledge, and attitudes.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: National policy changes such as increased financing and public reporting of quality metrics.
Number of subjects: 57
Study: 39266012

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 39266045

Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 67

Group type: COMPARATOR
Intervention: Selective surgery
Number of subjects: 67
Study: 39266205

Group type: EXPERIMENTAL
Intervention: Hysterectomy using an intrauterine manipulator
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Hysterectomy without an intrauterine manipulator
Number of subjects: 1030
Study: 39266213

Group type: EXPERIMENTAL
Intervention: HERV-E TCR-transduced T cells (HERV-E T cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39266309

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg QD orally for 3 days before surgery and 0.5 mg QOD for 10 days after surgery)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo (starch tablets for the same time and dosage)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 39266308

Group type: EXPERIMENTAL
Intervention: Intranodal administration of tolDCs loaded with heat shock protein 70-derived peptide mB29a, two intranodal injections of 5×10 (dosage not fully specified)
Number of subjects: 0
Study: 39266314

Group type: EXPERIMENTAL
Intervention: PRALIMAP-INÈS intervention
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Check-up visit by clinical research nurse
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Semistructured interview by sociologist
Number of subjects: 852
Study: 39266323

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 204

Group type: COMPARATOR
Intervention: Solifenacin succinate
Number of subjects: 204
Study: 39266535

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 160
Study: 39266619

Group type: EXPERIMENTAL
Intervention: DP303c administered intravenously every 3 weeks at doses of 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, and 4.0 mg/kg.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: DP303c
Number of subjects: 94
Study: 39266747

Group type: EXPERIMENTAL
Intervention: Triple combination of HIV-1 broadly neutralizing antibodies (bNAbs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy or cocktail of two antibodies
Number of subjects: 0
Study: 39266862

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (chemo+CHM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Chemotherapy combined with placebo (chemo+placebo)
Number of subjects: 180
Study: 39266891

Group type: EXPERIMENTAL
Intervention: Interactive text messaging (ITM) for alcohol use
Number of subjects: 188

Group type: COMPARATOR
Intervention: Behavioral intervention (MI)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Extended intervention (EI)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Brief intervention (BI)
Number of subjects: 188
Study: 39266938

Group type: EXPERIMENTAL
Intervention: Online biopsychobehavioral rehabilitation study including phosphodiesterase-5 inhibitors, sexual aids, pelvic floor exercise regimen, video, guide to good gay sex, and coaching.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Sexual aids (including vacuum pump, anal dilators, and penile constriction rings), masturbation, and pelvic floor exercises.
Number of subjects: 401

Group type: COMPARATOR
Intervention: Not applicable (control group not specified).
Number of subjects: 401
Study: 39266961

Group type: EXPERIMENTAL
Intervention: Escalating doses of CBD (5 mg CBD/kg/day to 30 mg CBD/kg/day, escalated every two weeks in increments of 5 mg CBD/kg/day)
Number of subjects: 40
Study: 39266985

Group type: EXPERIMENTAL
Intervention: Total Pulpotomy (TP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Root Canal Treatment (RCT)
Number of subjects: 64
Study: 39267006

Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delivery by obstetrician
Number of subjects: 0

Group type: COMPARATOR
Intervention: Birth in hospital
Number of subjects: 0
Study: 39267010

Group type: EXPERIMENTAL
Intervention: Exercise intervention (moderate intensity exercise with exercise physiologists 3 days/week for 16 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 39267015

Group type: EXPERIMENTAL
Intervention: Nanofortified adhesive (titanium dioxide nanoparticles)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional adhesive (without nanoparticles)
Number of subjects: 60
Study: 39267042

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) levels in patients with LVH
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Baseline levels of RC
Number of subjects: 630
Study: 39267052

Group type: EXPERIMENTAL
Intervention: COVID-19 incidence rate
Number of subjects: 32223

Group type: EXPERIMENTAL
Intervention: COVID-19 mortality rate
Number of subjects: 32223
Study: 39267085

Group type: EXPERIMENTAL
Intervention: MR-guided adaptive radiotherapy (MRgART) with simultaneous integrated boost (SIB) (60-65 Gy in 25-28 fractions to primary lesions and positive lymph nodes; 50-50.4 Gy in 25-28 fractions to the pelvis)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (50-50.4 Gy in 25-28 fractions)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups receive concurrent chemotherapy with capecitabine and consolidation chemotherapy of either two cycles of CAPEOX or three cycles of FOLFOX between radiotherapy and surgery
Number of subjects: 128
Study: 39267092

Group type: EXPERIMENTAL
Intervention: MI + video feedback observation (IO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MI + observation + vibratory feedback (IOV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MI alone (IA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MI + vibratory feedback (IV)
Number of subjects: 16
Study: 39267112

Group type: EXPERIMENTAL
Intervention: gamma transcranial alternating current stimulation (tACS) at 40 Hz for 30 one-hour sessions over 15 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 46
Study: 39267183

Group type: EXPERIMENTAL
Intervention: My Anesthesia Choice─Hip Fracture conversation aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active implementation period
Number of subjects: 0
Study: 39267224

Group type: COMPARATOR
Intervention: Online psychoeducational program
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Online psychoeducational program integrated with VR
Number of subjects: 100
Study: 39267408

Group type: EXPERIMENTAL
Intervention: MTx.100 Column plus standard of care (SOC), n=70
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard of care (SOC) only, n=244
Number of subjects: 107
Study: 39267574

Group type: EXPERIMENTAL
Intervention: Inosine (0.2 g, three times/day) + PD-1/PD-L1 inhibitor
Number of subjects: 172

Group type: COMPARATOR
Intervention: Non-inosine (PD-1/PD-L1 inhibitor ± targeted ± chemotherapy)
Number of subjects: 172
Study: 39267685

Group type: EXPERIMENTAL
Intervention: Personalized mRNA vaccine (1 mg every 3 weeks for 4 cycles) combined with PD-1 inhibitor therapy.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor therapy (single dose 8 weeks after the 4th cycle).
Number of subjects: 1
Study: 39268031

Group type: EXPERIMENTAL
Intervention: Transcranial temporal interference stimulation (tTIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 39268119

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) after early extubation for 48 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oxygen therapy (Venturi mask or nasal goggles) after early extubation for 48 hours
Number of subjects: 0
Study: 39268602

Group type: EXPERIMENTAL
Intervention: Higher mean levels of total cholesterol, LDL-C, and non-HDL-C
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: 1-SD increment of lipid variability (LDL-C)
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: Elevated variability in LDL-C and non-HDL-C
Number of subjects: 2395

Group type: EXPERIMENTAL
Intervention: Maintaining consistently low levels of atherogenic lipids
Number of subjects: 2395
Study: 39268670

Group type: EXPERIMENTAL
Intervention: Diastolic delta (DD) and videodensitometry assessment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diastolic delta (DD)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Videodensitometry
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cardiac magnetic resonance
Number of subjects: 51
Study: 39268699

Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of bepirovirsen in participants with hepatic impairment (HI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched healthy participants (HPs)
Number of subjects: 0
Study: 39268760

Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasty using a direct lateral approach
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasty using an anterolateral approach
Number of subjects: 23
Study: 39268857

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 730
Study: 39268981

Group type: EXPERIMENTAL
Intervention: Pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy (IFRT)
Number of subjects: 34
Study: 39269392

Group type: EXPERIMENTAL
Intervention: SC furosemide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 51
Study: 39269400

Group type: EXPERIMENTAL
Intervention: Operator performing ≥32 LAAOs annually
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Operators performing <32 LAAOs annually
Number of subjects: 1547
Study: 39269413

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion measured at rest and under stress using cardiac magnetic resonance; assessed myocardial blood flow (MBF) and myocardial perfusion reserve (MPR).
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Stress MBF measurements.
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Higher stress MBF and MPR.
Number of subjects: 453
Study: 39269415

Group type: EXPERIMENTAL
Intervention: PPG >0.65
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: FFR ≤0.70
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combined PPG >0.65 and FFR ≤0.70
Number of subjects: 95
Study: 39269606

Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 22
Study: 39269704

Group type: EXPERIMENTAL
Intervention: Complete SCH intervention (group 5)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: NP follow-up (group 3)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Self-management coaching (group 1)
Number of subjects: 757

Group type: COMPARATOR
Intervention: NP follow-up (group 4)
Number of subjects: 757
Study: 39269742

Group type: EXPERIMENTAL
Intervention: Self-Care Self-Efficacy Index in Oral Anticoagulation Therapy Management (SCSE-OAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCSE-OAC
Number of subjects: 0
Study: 39269759

Group type: EXPERIMENTAL
Intervention: Semaglutide with lifestyle counseling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lifestyle counseling without semaglutide
Number of subjects: 20
Study: 39269839

Group type: EXPERIMENTAL
Intervention: Real tACS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 46
Study: 39269850

Group type: EXPERIMENTAL
Intervention: 24(S)-Hydroxycholesterol (24(S)-OHC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24(S)-OHC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25-OHC and 27-OHC
Number of subjects: 0
Study: 39270145

Group type: EXPERIMENTAL
Intervention: Autologous Transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic Transplantation
Number of subjects: 0
Study: 39270146

Group type: EXPERIMENTAL
Intervention: 12 weeks of highly structured aerobic exercise training (AT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 64
Study: 39270144

Group type: EXPERIMENTAL
Intervention: IGLON5 autoantibodies
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: CASPR2 autoantibodies
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Symptoms associated with IGLON5 and CASPR2 cases
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Clinical implications of findings
Number of subjects: 339
Study: 39270151

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin (days 1-21) followed by clopidogrel (days 22-90)
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Aspirin alone for 90 days
Number of subjects: 6100
Study: 39270205

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation
Number of subjects: 84
Study: 39270307

Group type: EXPERIMENTAL
Intervention: Improved Hot Weather Combat Uniform (IHWCU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Army Combat Uniform (ACU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ACU with silk-weight base layer (ACU+)
Number of subjects: 12
Study: 39270380

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with chemotherapy
Number of subjects: 719

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 719
Study: 39270623

Group type: EXPERIMENTAL
Intervention: Baseline serum neurofilament light (NfL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum NfL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NfL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood NfL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defined thresholds of NfL
Number of subjects: 0
Study: 39270686

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin efsitora alfa
Number of subjects: 893

Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 893
Study: 39270695

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg once daily for patients with bodyweight ≥50 kg; 400 mg once daily for patients with bodyweight <50 kg, administered in 21-day cycles.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Savolitinib
Number of subjects: 87
Study: 39270701

Group type: EXPERIMENTAL
Intervention: Single dose of the intervention (specific intervention not provided in the abstract)
Number of subjects: 332
Study: 39270702

Group type: EXPERIMENTAL
Intervention: Atezolizumab, venetoclax, and obinutuzumab combination
Number of subjects: 28